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The increasing number of patients with coronary artery disease undergoing major non-cardiac
surgery justi®es guidelines concerning preoperative evaluation, stress testing, coronary angio-
graphy, and revascularization. A review of the recent literature shows that stress testing should
be limited to patients with suspicion of a myocardium at risk of ischaemia, and coronary angio-
graphy to situations where revascularization can improve long-term survival. Recent data have
shown that any event in the coronary circulation, be it new ischaemia, infarction, or revascular-
ization, induces a high-risk period of 6 weeks, and an intermediate-risk period of 3 months. A
3-month minimum delay is therefore indicated before performing non-cardiac surgery after
myocardial infarction or revascularization. However, this delay may be too long if an urgent
surgical procedure is requested, as for instance with rapidly spreading tumours, impending
aneurysm rupture, infections requiring drainage, or bone fractures. It is then appropriate to
use perioperative beta-block, which reduces the cardiac complication rate in patients with, or
at risk of, coronary artery disease. The objective of this review is to offer a comprehensive
algorithm to help clinicians in the preoperative assessment of patients undergoing non-cardiac
surgery.
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Contemporary medicine shows a trend towards more
aggressive surgery in sicker patients, among whom the
prevalence of ischaemic heart disease is increasing. This
tendency creates a requirement for guidance in the
preoperative evaluation of patients known to have, or at
risk of, coronary artery disease. There is an abundance of
studies on this subject, but the way to evaluate these patients
is still the object of considerable debate. Much of the
controversy is because of the obvious dif®culties of
conducting large randomized controlled clinical trials on
this topic, and to the relatively low incidence of periopera-
tive cardiac events (<10%). The rate of postoperative
myocardial infarction is 0.7% after general surgery in a
male population over 50 yr old, but increases to 3.1% after
vascular surgery where the prevalence of asymptomatic
coronary artery disease is particularly high.3 53 61 Because of
this prevalence, most of the studies have focused on
vascular patients, who represent less than 10% of the adult
surgical population. This fact may introduce a bias when the
results are extrapolated to other surgical cohorts.
The purpose of preoperative evaluation is to lower
perioperative morbidity and mortality with minimal
expense from preoperative testing, and to concentrate
economic investment on high-risk patients where special-
ized tests might modify perioperative management and
improve long-term bene®t. Testing a low-risk population
not only increases costs unnecessarily, but may increase
morbidity and causes harm by delaying a non-cardiac
operation. The main question to be answered is: does the
patient need cardiological testing? When coronary artery
disease is present, three other questions arise: may the
patient bene®t from coronary revascularization? Is non-
cardiac surgery so imperative that it should be carried out
rapidly despite the risk? Is it possible to decrease this risk?
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As the workload resulting from perioperative ischaemic
cardiac evaluation is signi®cant, clinicians need practical
guidelines for their daily practice. This review aims to offer
them an update on the literature on preoperative assessment
of patients known to have, or at risk of, coronary artery
disease undergoing non-cardiac surgery. It also presents an
evaluation algorithm used in our institution. The level of
evidence in the studies cited in the text is mentioned in the
references.
Clinical predictors
Despite sophisticated technologies, history and physical
examination of the patient remain the key elements of
preoperative risk assessment. Risk strati®cation of patients
with known, or at risk of, coronary artery disease is usually
based on three elements:115 (i) the patient risk factors;
(ii) functional capacity of the patient; and (iii) the risk
factors of surgery.20 The vast majority of the studies has
been performed in North America and among Veterans
Administration Hospitals, the population of which consists
mainly of elderly white male patients. However, the
prevalence of coronary artery disease and its morbidity
varies considerably in different countries. For example, the
incidence of infarction among patients with abdominal
aortic aneurysm is 16% in France, but 50% in Sweden.4 55
Similarly, there are ethnic differences in the response to
treatment between white and non-white populations.24 124
Thus, it may be inaccurate to transpose the results of one
population to another. On the other hand, the risk of surgery
is highly dependent on surgical skills, anaesthetic care, and
nursing quality. Each institution should therefore establish
its own audit in order to take appropriate decisions when
choices have to be made between different treatment
modalities.
Risk factors of the patients
Risk factors of the patients are usually subdivided into three
categories: major, intermediate, and minor (Table 1). Major
predictors are markers of unstable coronary disease and
include: recent myocardial infarction (<6 weeks), unstable
or severe angina (class III±IV), ongoing ischaemia after
myocardial infarction, ischaemia and congestive heart
failure, or malignant arrhythmias. New or changing symp-
toms suggest atheromatous plaque rupture and should be
presumed to be infarction unless proven otherwise. A
6-week period is necessary for the myocardium to heal after
an infarction and for the thrombosis to resolve.116 Patients
with coronary revascularization done within the preceding
40 days should also be classi®ed as high-risk patients.79
Because of sympathetic stimulation and hypercoagulability
during and after surgery, patients with major predictors have
a ®ve times greater perioperative risk.20 84 Only vital or
emergency surgical procedures should therefore be con-
sidered for these patients. All elective operations should be
postponed and the patients properly investigated and
treated.
Intermediate-risk factors, such as previous myocardial
infarction (>6 weeks and <3 months) without sequelae or
threatened myocardium, stable angina (class I±II) with
optimal medical treatment, or documented previous peri-
operative ischaemic events, are independent predictors for
perioperative cardiac complications; they are proof of well
established but controlled coronary artery disease. Diabetes
mellitus is included in this category because it is frequently
associated with silent ischaemia, and represents an inde-
pendent risk factor for perioperative mortality, as do low
ejection fraction (EF <0.35) and compensated heart
failure.20 65 The relevance of advanced age (>70 yr),
hypertension and left ventricular hypertrophy (LVH) to
the intermediate or minor risk category is still controversial.
American guidelines tend to consider age as a minor factor
but, if it is estimated by physiological age and not
chronological age, it should belong to the intermediate
category.20 22 50 65 93 101 The presence of hypertension
among intermediate or minor risk categories depends
probably on the population studied, as it is an easily
controllable factor in the perioperative period.57 LVH has
been considered as an independent marker of ischaemic
disease and cardiac complications, but recent recommen-
dations tend to consider it a minor factor.17 33 37 65 76 Risk
Table 1 Classi®cation of cardiac risk factors linked to patient status
modi®ed from references.20 22 64 69 83 92 114 CABG=coronary artery bypass
graft
Major factors (markers of unstable coronary artery disease)
Myocardial infarction <6 weeks
Angina class III±IV
Residual ischaemia after myocardial infarction
Clinical ischaemia and congestive heart failure
Clinical ischaemia and malignant arrhythmias
CABG or PTCA <6 weeks
Intermediate factors (markers of stable coronary disease)
Prior myocardial infarction >6 weeks and <3 months (>3 months if
complicated) by clinical history or ECG abnormalities
Angina class I±II
Asymptomatic patient post infarction with maximal therapy
Documented previous perioperative ischaemia
Silent ischaemia (Holter monitoring)
Post CABG or PTCA >6 weeks and <3 months, or >6 yr, or with anti-anginal
therapy
Ventricular arrhythmia
Diabetes mellitus
Age (physiological) >70 yr
Compensated or prior heart failure, ejection fraction <0.35
Minor factors (increased probability of coronary artery disease)
Familial history of coronary artery disease
Polyvascular status
Uncontrolled systemic hypertension
Hypercholesterolaemia
Smoking
ECG abnormalities (arrhythmia, LVH, bundle branch block)
Post infarction (>3 months), asymptomatic without treatment
Post CABG or PTCA >3 months and <6 yr, and no symptoms of angina nor
anti-anginal therapy
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factors are additive: complication rates increase with their
number, as does the necessity to investigate the patients.65 76
Minor risk factors are markers of an increased probabil-
ity of coronary artery disease, but not of an increased
perioperative risk; they are mentioned in Table 1.2 In
patients asymptomatic within 6 yr after coronary artery
bypass grafting (CABG) or percutaneous transluminal
coronary angioplasty (PTCA), evidence suggests that the
risk of subsequent non-cardiac surgery is the same as in non-
coronary patients, as long as the delay of 3 months is
respected after revascularization, and the stress tests are
negative within the previous 2 yr.21 22 26 37 85 111
Functional capacity
Exercise tolerance is a major determinant of perioperative
risk.20 22 42 81 It is usually evaluated by the estimated energy
requirement for various activities, and graded in metabolic
equivalents (MET) on a scale de®ned by the Duke Activity
Status Index (Table 2).54 One MET represents the oxygen
consumption of a resting adult (3.5 ml kg±1 min±1).
Ergometric measurements on a treadmill inducing ischae-
mia at low-level exercise (<5 MET or heart rate <100 min±1)
identi®es a high-risk group, whereas the achievement of
more than 7 MET (or heart rate >130 min±1) without
ischaemia identi®es a low-risk group.122 Vascular patients
who are able to exercise to 85% of their maximal heart rate
have a low risk of a perioperative cardiac event.78 More
simply, the inability to climb two ¯ights of stairs is
associated with a positive predictive value of 89% for
cardiopulmonary complications.42 In the absence of valve
pathology, the ejection fraction of the left ventricle can be
considered as an adequate measurement of the myocardial
functional reserve.100 Patients with good functional capacity
and no symptoms can be considered free of any severe
coronary artery disease.86 Despite its predictive value in the
perioperative setting, the Duke Activity Status Index has
never been speci®cally tested for ischaemic patients.84
Risk factors associated with surgery
Surgical procedures can be strati®ed into three categories,
according to their level of perioperative physiological stress
(Table 3).20 22 When estimating the risk of an operation, one
must also take into consideration the risk of not operating on
the patient. This evaluation is particularly important for
oncological or limb salvaging procedures. It is unethical to
reject a patient when their survival is threatened by the
diseaseÐas with rapidly spreading tumours, impending
aneurysm rupture, infections requiring surgery, or disabling
bone fractures. In order to balance the risks, it might be
necessary to limit the extent of the planned procedure, or to
plan repeated operations. Risk reduction strategies must also
be applied, such as maintaining normothermia, avoiding
extreme anaemia, controlling postoperative pain, and pre-
scribing perioperative beta-block.76 107 127 The performance
of the individual institution must be taken into account,
as it is a determinant factor in the success of particular
procedures.
Previous ischaemia
During the 1980s, the rule prevailed to wait 6 months after a
myocardial infarction before embarking on non-cardiac
surgery.97 109 114 Since then, the cardiological management
and the functional assessment of patients have evolved
signi®cantly. It appears now that the risk after a previous
infarction is related less to the age of the infarction than to
the functional status of the ventricles and to the amount of
myocardium at risk from further ischaemia, as evaluated
during convalescence.22 104 105 A small infarction without
residual angina in the context of a good functional status
allows essential non-cardiac surgery as soon as 6 weeks
after the ischaemic episode.115 On the contrary, a patient
with a large infarct, residual symptoms and ejection fraction
below 0.35 has a high probability of a further cardiac event,
even 6 months after the infarction. Usual practice guidelines
consider the period within 6 weeks of infarction as a time of
high risk for a perioperative cardiac event, because it is the
Table 2 MET in increasing order (Duke Activity Status Index) (adapted
from Hlatky, 198954)
1±4 MET Standard light home activities
Walk around the house
Walk 1±2 blocks on level ground at 3±5 km h±1
5±9 MET Climb a ¯ight of stairs, walk up a hill
Walk on level ground at >6 km h±1
Run a short distance
Moderate activities (golf, dancing, mountain walk)
>10 MET Strenuous sports (swimming, tennis, bicycle)
Heavy professional work
Table 3 Cardiac risk classi®cation of non-cardiac surgical procedures
adapted from ACA/AHA guidelines for perioperative cardiovascular
evaluation for non-cardiac surgery20 22
Minor procedures (cardiac complication rate <1%)
Endoscopic procedures
Ambulatory surgery
Breast and super®cial procedures
Eye surgery
Plastic and reconstructive surgery
Intermediate procedures (cardiac complication rate 1±5%)
Minor vascular surgery, including carotid endarterectomy
Abdominal and thoracic procedures
Neurosurgery
ENT procedures
Orthopaedic surgery
Prostatectomy
Major procedures (cardiac complication rate >5%)
Emergency intermediate and major procedures
Aortic and major vascular surgery
Prolonged surgical procedures, large ¯uid shifts or blood loss
Unstable haemodynamic situations
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mean healing time of the infarct-related lesion.22 80 116 The
period from 6 weeks to 3 months is of intermediate risk; this
period is extended beyond 3 months in cases with
complications such as arrhythmias, ventricular dysfunction,
or continued medical therapy.1 In uncomplicated cases, no
bene®t can be demonstrated for delaying surgery more than
3 months after an ischaemic accident.115
Previous coronary revascularization
Patients who do well after CABG have an attenuated risk of
cardiac events during subsequent non-cardiac surgery.
Retrospective studies have disclosed a signi®cant improve-
ment in survival of revascularized patients, particularly
those with triple-vessel coronary artery disease and
depressed ventricular function, when they undergo subse-
quent non-cardiac vascular surgery.85 98 110 In the Coronary
Artery Surgery Study (CASS) experience, these patients
have a mortality of 0.9%, instead of 2.4% for those who
have not been revascularized;37 recent data show the same
trend.51 However, when the complication and mortality
rates of CABG are taken into account, the combined
mortality of cardiac and non-cardiac procedures is not
different from the mortality of non-cardiac surgery when
ischaemic heart disease has been managed by medical
treatment only.37 A patient might therefore bene®t from
preoperative coronary revascularization if the CABG pro-
cedure presents a low risk and will improve long-term
survival, and if the planned non-cardiac procedure is high
risk but can wait for at least 3 months.
The short-term effect of prophylactic CABG among
vascular patients has been addressed in two decisional
analyses; both showed it was safer to proceed directly with a
non-cardiac operation and close monitoring before coronary
revascularization.31 75 The bene®t of coronary revascular-
ization might be even lower among patients undergoing
non-vascular surgery, as they have already a lower
probability of perioperative cardiac events.3 84 Obviously,
there is no indication to advise prophylactic revasculariza-
tion in order to protect the ischaemic myocardium from the
effects of a subsequent non-cardiac operation. The indica-
tions for coronary revascularization are aimed at reducing
long-term mortality and prolonging survival.33 36 75 They
are the same in patients being evaluated for a non-cardiac
operation as for non-surgical population and include:
unstable angina, left main coronary artery disease, three-
vessel disease, proximal left anterior descending artery
disease, and decreased ventricular function.
Asymptomatic, functionally active patients with previous
successful coronary revascularization within the last 6 yr are
in a low-risk category and should not be investigated further
for a non-cardiac operation; this cut-off point is based on a
slight but non-signi®cant increase in postoperative infarc-
tion rate among patients 6 yr after CABG surgery.21 Patients
having a negative stress test or satisfactory angiography in
the last 2 yr can be cleared for non-cardiac surgery without
further testing, if the symptomatology and treatment have
not changed since the examination.20 22
In the 1990s, it seemed that PTCA had a signi®cant
protective effect on the ischaemic complications of subse-
quent non-cardiac surgery. In two studies from the Mayo
Clinic, major vascular surgery was performed on average 11
days after PTCA;27 58 overall mortality of surgery was
halved and infarction rate ®ve times less in the groups
having previous PTCA compared with non-revascularized
patients. Such results with dilatative angioplasty have been
repeated, showing improvement in vascular surgery out-
come for patients having undergone PTCA 11 days to 18
months earlier.45 However, with the advent of stenting
during PTCA, recent studies have heralded fundamentally
different results. In one study, there were eight deaths and
seven myocardial infarctions among 40 patients who
underwent coronary stent placement less than 2 weeks
before non-cardiac surgery.60 In addition, patients under-
going non-cardiac surgery within 40 days of PTCA are
nearly three times more likely to have an adverse cardiac
event than normal controls, and are no less likely to have a
poor cardiac outcome than non-revascularized patients until
90 days after PTCA.92 Any surgery performed within 6
weeks of PTCA presents an excessive risk of stent
thrombosis and infarction if the antiplatelet medication is
stopped, or of major bleeding if the treatment is maintained
throughout the operation.22 79 119 This is a period of major
risk: most of the re-stenoses requiring repeat PTCA occur
during the ®rst months after stenting, and documented stent
thrombosis is associated with a mortality rate of 7%.15 17
The optimal timing for surgery is therefore a delay of 3
months after PTCA and stenting. Compared with PTCA,
CABG with internal mammary grafting has a better long-
term protective effect, particularly in diabetic patients;38 the
rate of late cardiac events (>3 yr) is halved in surgically
revascularized patients.27 35
Preoperative testing
Preoperative testing is aimed at answering precise questions
raised by clinical history and examination. No cardio-
vascular test should be performed if the results will not
change perioperative management. The therapeutic impact
may differ according to the situation: medical treatment
may be optimized, surgical procedure modi®ed, anaesthetic
management adjusted, or the risk/bene®t ratio of a surgical
procedure evaluated differently. These complex decisions
can be taken more objectively when the actual risk can be
quanti®ed by appropriate screening tests.70 However, no
magic test will ever exist to fully stratify all risks, because
perioperative cardiac events are multifactorial.84
The indication for preoperative tests is based on Bayes'
theorem, which speci®es that the predictive value of testing
is optimized when it is applied to an intermediate-risk
population (Table 1), as the incidence of false negatives
and false positives is inversely proportional to disease
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prevalence. The probability of a complication is a function
of the probability of the disease in the category to which the
patient belongs. In such a Bayesian model using clinical
predictors and results of dipyridamole-thallium scintigraphy
(DTS), it appears that modi®cations are introduced by the
test only in the intermediate-risk patient category.66 Without
symptoms of angina, previous infarction or heart failure, the
probability of suffering from coronary artery disease is 6%;
if diabetes is also excluded, the probability falls to 4%;86
further testing of such a patient has an extremely low impact
on complication rate. Similarly, the outcome of a patient
with a clear history of active coronary artery disease will not
be modi®ed by screening tests.
Stress tests (exercise ECG, DTS, or dobutamine
echocardiography) are dynamic investigations, which
demonstrate the ischaemic threshold, the maximal tolerated
heart rate, the localization, and the amount of threatened
myocardium. An interruption of the test before reaching the
maximal theoretical heart rate identi®es an increased risk of
perioperative ischaemic events.70 The positive predictive
value of all stress tests is modest (20±30%), whereas their
negative predictive value is excellent (95±100%); this
should not be surprising, as the incidence of perioperative
cardiac complications is low (<10%) and more than 90% of
patients have a straightforward perioperative course.10 In a
meta-analysis of the predictive value of four preoperative
tests (DTS, ejection fraction estimated by radionuclide
ventriculography, ambulatory electrocardiography, and
dobutamine stress echocardiography (DSE)), DSE appears
more discriminating, but the data do not allow selection of
an optimal test because of overlapping con®dence intervals
(Table 4).73 DSE seems particularly informative because it
investigates the segmental coronary blood supply and
allows simultaneous quanti®cation of ventricular function.
The pertinence of tests is increased for multi-vessel
disease, but diminished in cases of isolated single-vessel
stenosis.41 Beside the speci®cities of each test, it is the
expertise of its medical interpretation and the characteristics
of the population in which it is applied which alters its
impact. Such differences may introduce signi®cant bias
when comparing the ef®ciency of these tests in predicting
outcomes. The comparison of various studies is further
confounded because some are based on consecutive case
recruitment, whereas others analyse selective testing of
classes of patients.33
Electrocardiography (24 h Holter monitoring)
Preoperative ambulatory ECG (Holter monitoring) is rela-
tively inexpensive but may be dif®cult to analyse because of
electrocardiographic abnormalities precluding adequate
interpretation in up to 50% of patients.95 One highly
powered study demonstrated that the detection of silent
preoperative ischaemia has a positive predictive value of
38% for postoperative cardiac events, whereas its absence
precludes perioperative problems in non-vascular surgery in
99% of patients and in vascular surgery in 86%.30 When
electrocardiographic criteria of LVH were added to ST
segment depression, the preoperative Holter ECG became
signi®cantly predictive of postoperative events.62 However,
other studies show less clear-cut data, and results are not
unanimous in non-cardiac surgery, probably because post-
operative ischaemia is primarily a result of ischaemic events
occurring during surgery.67 69 95 Perioperative stress and
techniques of patient management are probably more
determinant features than the presence of preoperative
electrocardiographic signs of ischaemia.
Exercise ECG
The exercise ECG is a widely available and inexpensive
method of screening for coronary artery disease but depends
on the exercising ability of the patient and the legibility of
the ECG. Often, vascular patients do not reach the target
heart rates because of limb claudication, and therefore have
an inadequate examination. In patients who can perform the
test, studies conducted in vascular and non-vascular patients
are not conclusive for its ability to predict perioperative
cardiac complications.32 41 59 113 However, a recent pro-
spective study on intermediate-risk patients con®rmed that a
ST-segment depression of 0.1 mV or more during exercise
is an independent predictor of perioperative ischaemic
events.39 Because of its availability and low cost, the
exercise ECG should be considered as the ®rst screening
step in stress testing for non-vascular patients with a normal
ECG and good mobility.20
Dipyridamole-thallium scintigraphy
When myocardial perfusion is increased by vasodilation
with dipyridamole, infarcted areas appear as ®xed defects,
whereas ischaemic myocardium appears as defects, which
Table 4 Comparison of three preoperative stress tests. *Relative risk is the probability of a cardiac event when a test result is positive divided by the
probability of that event when the test result is negative (modi®ed from Mantha73). **Cost at the University Hospital of Lausanne (CHUV), Switzerland
Test Median relative
risk*
Sensitivity
(%)
Speci®city
(%)
Positive predictive
value (%)
Cost**
(=C)
Ambulatory ECG (Holter) 2.7 68 66 25 190
Exercise ECG 69 73 20 220
Dipyridamole-thallium 4.6 85 80 23 410
DSE 6.2 80 90 30 570
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are reversible when reperfused on later images. There is an
incremental increase in the probability of postoperative
cardiac events with increasing size and number of these
defects.12 14 Reversible defects are ef®cient markers of the
myocardium at risk, and are clearly associated with an
adverse cardiac event.19 Quanti®cation of their delayed
redistribution at 4±24 h is more predictive of cardiac death
or myocardial infarction than simple dichotomous inter-
pretation in positive/negative results.32 108 118 There is
strong evidence that DTS has a good predictive value for
determining a low or high operative risk when applied to a
selected population of clinical intermediate-risk, vascular
patients.66 118 However, it has no real screening value, when
applied to a large unselected vascular or non-vascular
population, or among patients already classi®ed clinically as
low- or high-risk candidates for surgery.4 68
Left ventricular ejection fraction
There is strong evidence that simple assessment of the
resting ejection fraction by transthoracic echocardiography
alone does not improve prediction of ischaemic complica-
tions in cardiac patients, although it is useful for evaluating
outcome in current or poorly controlled heart failure.22 49 77
A depressed ejection fraction predicts only postoperative
left ventricular dysfunction and correlates better with late
than early postoperative cardiac events.83 102 Technetium-
99 radionuclide angiography offers a more precise and more
reproducible measurement, but is not a better predictor of
ischaemic events.117
Dobutamine stress echocardiography
An increase in oxygen demand following dobutamine
perfusion (40 mg kg±1 min±1) is more discriminative, as it
can induce wall motion abnormalities pathognomonic of
ischaemic myocardium. According to most meta-analyses,
it offers the best prediction for perioperative events, with a
negative predictive value close to 100% and a positive
predictive value up to 38% among intermediate- or high-risk
patients (Table 4), even if it does not add discriminative
power in patients with no clinical markers of coronary artery
disease.11 23 74 84 88 108 Patients demonstrating extensive
ischaemia under dobutamine stimulation (>5/16 left ven-
tricular segments involved), experience 10 times more
cardiac events than patients with limited stress-induced
ischaemia (<4 segments involved).11 Based on a Dutch
study of 1351 consecutive patients undergoing major
vascular surgery, DSE can be considered as an effective
test for identifying the small group (2%) of patients at high
ischaemic risk who should undergo coronary angiogram and
possible revascularization. In contrast, patients with
moderate risk (<4 segments involved) could undergo
surgery directly under beta-block protection.11
Coronary angiography
Coronary angiography is an invasive procedure, which
carries mortality of 0.01±0.05%, and a morbidity of
0.03±0.25%.75 It is indicated only in cases of unstable
coronary syndromes, of uncertain stress tests in high-risk
patients undergoing major surgery, or when there is a
possible indication for coronary revascularization.22 When
the coronary artery disease is diffuse in small vessels, as in
subendocardial ischaemia without wall motion abnorm-
alities, or when the patient is not a candidate for
revascularization because of comorbid states, coronary
angiography has little impact, as the probability of the
results leading to PTCA or CABG is very low.104 Coronary
angiography should therefore be performed before a non-
cardiac operation only in high-risk patients who warrant
coronary revascularization for medical reasons, irrespective
of the preoperative context.
Test limitations
Predictions are only probabilities of events: a negative
preoperative test in a particular patient, although reassuring
for the anaesthetist, does not mean that cardiac complica-
tions are excluded. Independent of its prognostic capacity,
each test has its own advantages and contraindications
(Table 5). More importantly, the primary factor for deciding
the most ef®cient test is institution-speci®c: the best
prediction will be provided by the most quali®ed depart-
ment, whether it is cardiology, nuclear medicine, or the echo
laboratory.
The concept that postoperative ischaemia and infarction
are related to perioperative excess oxygen demand is
supported by the fact that ischaemic events peak at the
second and third postoperative day, whereas tachycardia is
maximum during days 1 and 2.69 Patients with higher
maximum heart rates after surgery have more ischaemic
episodes and a longer cumulative duration of ischaemia.96
There is a strong correlation between immediate post-
operative ischaemia (ST-segment depression) and cardiac
events supervening after surgery.67 Nowadays, stress
echocardiography is the closest replication of an equivalent
increase in myocardial oxygen consumption. Nevertheless,
there is no test that adequately mimics the physiological
stress response to surgery, with prolonged sympathetic
stimulation and tachycardia, increased coronary vasomotor
tone, hypercoagulability, potential atheromatous plaque
rupture leading to thrombus formation, hypothermia, and
blood loss.28 33 107 Moreover, the culprit lesion causing
myocardial infarction often occurs in a insigni®cantly
stenosed coronary vessel.26 43 Although DTS and DSE
have good predictive accuracy in patients undergoing
vascular surgery,87 88 they seem not as ef®cient in patients
undergoing non-vascular operations.63 125 Without pro-
spective studies on selected populations, it is not yet
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possible to de®ne the real impact of stress tests on outcome
in general surgery.
Patients receiving effective chronic beta-block are dif®-
cult to evaluate with stress tests because they have a limited
increase in heart rate and cardiac output on exercise. The
sensitivity of stress tests for diagnosing a coronary lesion is
signi®cantly lowered under these circumstances.29 123
However, as a preoperative prognostic tool, these tests
retain their full value, as they demonstrate which level of
stress these patients can endure before showing myocardial
ischaemia under the protection of beta-adrenergic antagon-
ism. The decreased incidence of ischaemic modi®cations
with beta-block is a diagnostic drawback, but is nevertheless
a demonstration of the level of protection reached with this
medication.
Testing takes time and money. Only intermediate-risk
(Table 1), and low-functional status (Table 2) patients,
undergoing major or vascular surgery (Table 3) bene®t from
stress testing. High-risk patients should undergo coronary
angiography. In a theoretical model of decision analysis,
using as an end-point mortality rates for abdominal aortic
aneurysm resection and CABG, Glance44 suggests that
preoperative screening, in which high-risk patients proceed
directly to angiography and possible CABG, intermediate-
risk patients are ®rst screened with DTS, and low-risk
patients undergo no testing before vascular surgery, may
improve 5-yr survival from 77 to 86%. In this model, routine
testing of all patients is of no bene®t compared with
selective testing of the intermediate-risk category, and is
more expensive. Some patients have an obvious indication
for urgent surgery and yet have a clinical coronary status,
which would require investigation because of the possible
need for revascularization. Testing and treating them would
impose an unacceptable delay in the surgical treatment of
the life-threatening primary disease. In such a case, it is not
indicated to thoroughly investigate the patient, as the
decision to operate with the shortest delay is made whatever
the results. Based on recent data on risk strati®cation, it can
be asserted that these emergency operations can be
performed as soon as possible, but should be accompanied
by perioperative treatment with beta-blockers.11 90 127
Diabetes mellitus
In diabetic patients, the risk of coronary artery disease is two
to four times higher than in the corresponding general
population.2 Moreover, diabetes is frequently associated
with silent ischaemia; if detected by Holter monitoring, it
has a positive predictive value of 35% for postoperative
cardiac events.30 Asymptomatic diabetic patients have an
incidence of ischaemic events similar to patients with stable
coronary artery disease.48 Clinicians should have a low
threshold for cardiac testing in diabetics, as the following
factors must be added to the usual minor clinical predictors
(Table 1): obesity, physical inactivity, albuminuria, dys-
lipidaemia, and age more than 55 yr.103 Chronically
elevated glucose (>11 mmol litre±1) and glycosylated
haemoglobin levels greater than 7% are better predictors
of cardiac events than the simple presence of dia-
betes.16 47 103 Diabetics with proven coronary artery disease
(intermediate-risk predictors) have a much poorer long-term
outcome after vascular surgery, with an increased prob-
ability of cardiac death or myocardial infarction compared
with non-diabetics with equivalent coronary artery
disease.12 14
Asymptomatic diabetic patients with two or more risk
factors should be investigated by stress testing if they have a
low-functional capacity (Table 2), or if they are to undergo
major or vascular surgery. Only individuals with good
functional capacity undergoing minor or intermediate
surgery (Table 3) can proceed directly to surgery. This is
a more aggressive attitude than for the general population.
The modi®cation of hypoglycaemic symptoms with beta-
Table 5 Advantages and disadvantages of preoperative tests
Test Advantages Disadvantages
Tests for myocardial perfusion
Ambulatory ECG (Holter) Simple, non-invasive Baseline ECG abnormalities restrict diagnostic possibilities, poor
predictive ability
Exercise ECG Simple, non-invasive Relies on patient mobility, baseline ECG abnormalities restrict
diagnostic possibilities, poor predictability in vascular patients
DTS Sensitivity 85%, speci®city 80% Contraindicated in unstable angina and asthma, delayed images
at 4 to 24 h use of radioactive material, requires overnight fasting
DSE Sensitivity 80%, speci®city 90%,
ventricular function detects dynamic ischaemia
Depends on transthoracic echogenicity, operator-dependent
Tests for myocardial function
Transthoracic echo Simple, rapidly available Diagnostic only in case of transmural ischaemia, no predictability
for ischaemia
Technetium-99 scanning No interobserver variability,
high reproductibility
Expensive, less availability
Evaluation of patients: coronary artery disease
753
blockers does not preclude their use in diabetics, as they
offer a perioperative protection against ischaemia.47 127
Vascular surgery
Preoperative evaluation for coronary ischaemia most fre-
quently involves vascular surgical patients, even if they are
asymptomatic because of limitations in physical activity:
37% of surgical vascular patients without symptoms of
myocardial ischaemia have signi®cant coronary disease at
angiography, and 15% have disease that warrants interven-
tion.1 52 53 The perioperative infarction rate in vascular
surgery is three times higher than in non-vascular surgery.61
The mortality rate for non-cardiac vascular surgery in
patients with coronary artery disease is 5±9%, whereas it is
only 1±2% in patients free of coronary disease, or in patients
who have had previous CABG.37 40 53 The incidence of
perioperative non-fatal myocardial infarction in vascular
surgery is 8.5% when the patients have proven coronary
artery disease, but only 1.6% in patients with no risk factors,
and 1.9% if the patient has had a CABG;21 118 the latter
results are obtained in patients who survived at least 6
months after their cardiac operation.
The data might seem to support prophylactic CABG.
However, the mortality/morbidity of coronary revascular-
ization, of a non-cardiac procedure and of postponement of
vascular surgery must be added.28 31 The mortality of
vascular patients in cardiac surgery (6.5%) is much higher
than the mortality of patients without vascular disease
(0.5±2%).8 31 50 82 98 99 Prior CABG offers no short-term
bene®t to these patients. In a decision analysis study
comparing the strategy of prior coronary revascularization
vs proceeding directly to vascular surgery, Mason and
colleagues found poorer overall short-term outcomes with
the combined procedures for the four end points of non-fatal
myocardial infarction, stroke, cost, and mortality.75 The
indication for revascularization is the potential long-term
bene®t of an increased survival, independent of non-cardiac
operative events. Routine coronary angiography in vascular
patients does not provide short-term perioperative bene®t.44
In a retrospective study on 6895 US Medicare patients, it
appears that coronary revascularization has a protective
effect on cases undergoing abdominal aortic surgery (fall in
mortality from 4.1 to 2.8%), but not on those who
underwent infra-inguinal vascular surgery.35 In older
patients (>70 yr), the bene®t of previous coronary
revascularization is probably non-existent, as mortality
correlated to CABG or PTCA increases with age and the
potential life-prolonging effect decreases. Finally, the
bene®t from CABG or PTCA may vary considerably
between different institutions or different surgeons: when
the perioperative mortality of abdominal aortic surgery is
low (<3%), preoperative testing for coronary artery disease
becomes insigni®cant in modifying the clinical outcome,
and previous revascularization is no longer necessary in all
but highly symptomatic patients.106
Pharmacological pretreatment
Is any pharmacological perioperative treatment protective
against ischaemia? In the past, controlled studies with
nitrates, calcium-channel blockers, clonidine, or digoxin
have all produced negative answers.7 13 18 25 94 More recent
prospective randomized studies have focused on the use of
beta-blockers with favourable results.127 In both vascular
and general surgery, the cardiac perioperative mortality is
reduced by 8% and the ischaemic complication rate by 15%
in patients treated with atenolol.71 Among vascular patients
with abnormal DSE, cardiac mortality, and morbidity are
lowered from 34% in a control group to 3.4% in a group
treated with bisoprolol.90 Perioperative beta-block reduces
the mortality of vascular patients in all risk categories
except in patients with unstable coronary syndromes
needing revascularization, as indicated by extensive ischae-
mia induced at DSE.11 The treatment is started a few days
before surgery, and continued during the ®rst postoperative
week. The dose is titrated to achieve a resting heart rate
between 50 and 60 beats min±1.22 Older age is not a
contraindication.126 If preoperative administration is not
possible, i.v. beta-block at the start of anaesthesia, followed
by continuous postoperative treatment, is also ef®cient.120
During a 3-yr follow-up, continuous administration of
bisoprolol also protects from late ischaemic cardiac events
after vascular surgery.89 91 As sympathetic stimulation and
tachycardia are among the most important factors in the
development of perioperative myocardial ischaemia, and as
ischaemia might appear in an insigni®cantly stenosed
coronary artery, it is not surprising that sympathetic block
is an effective method of preventing cardiac morbidity and
mortality in non-cardiac surgery, as it is in non-surgical
patients after myocardial infarction.26 43 46 69 There might
be non-responders, as recent investigations have disclosed
less effect of beta-block in American black individuals than
in the white population.24 124
As a consequence, in patients with known, or at risk of
coronary artery disease, beta1-selective antagonists should
be considered in the perioperative period when these
patients are to undergo major or vascular surgery. Despite
the concern of many anaesthetists, the bene®ts of fewer
cardiac complications in patients with coronary artery
disease outweigh the risks of adverse effects in stage IV
peripheral arterial disease, diabetes, and obstructive lung
disease.11 34 112 121 127 In most cases, the risk of non-cardiac
surgery alone with prophylactic beta1-block is lower than
the cumulative risk of coronary angiography, a revascular-
ization procedure and a non-cardiac vascular operation.10 64
Nevertheless, the recent trend towards beta1-antagonism
is essentially based on six publications summing up a
total of 502 patients receiving perioperative beta-
block.11 71 90 91 120 126 Only three of them are randomized
(total, 201 beta-block patients),71 90 126 and only two are
outcome studies (158 beta-block patients vs 154 controls,
short- and long-term follow-up).71 90 91 120 Obviously, more
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studies are needed before this therapy can be presented as
state-of-the-art management.
Algorithm
The American College of Cardiology/American Heart
Association Guidelines for Perioperative Cardiovascular
Evaluation for Noncardiac Surgery have promoted recom-
mendations based on evidence and expert opinions, and
summarized them in a decisional algorithm which has
proven ef®cient and cost-effective when tested on clinical
patients for vascular surgery.5 20 22 The American College
of Physicians has adopted a position based on a meta-
analysis of studies considered of strong, fair, or weak
quality, and proposed an algorithm based on a modi®ed
cardiac risk index;1 84 vascular and non-vascular surgery are
separated. Other workers have published their own views on
preoperative cardiac assessment, and have suggested useful
paradigms.36 56 72 74 115
In our proposition (Fig. 1), the algorithm starts with a
strati®cation of patients in three categories on the basis of
clinical predictors (Table 1): low-risk (increased probability
of coronary artery disease), intermediate-risk (stable
coronary artery disease), and high-risk (unstable coronary
syndrome). It proceeds through two evaluation steps: the
exercise tolerance of the patient (cut-off point between 4
and 5 MET, Table 2) and the importance of the surgical
procedure (minor, intermediate, or major, Table 3). Stress
tests are performed only in the intermediate-risk category.
Coronary angiography is considered in patients with
unstable coronary syndromes or with stress tests revealing
large areas of myocardium at risk. High-risk patients should
undergo only mandatory or emergency procedures; anaes-
thesia should then be provided by an experienced
anaesthetist using invasive monitoring and aggressive
treatment of haemodynamic or ischaemic abnormalities.
The choice of anaesthesia technique, like use of epidural
analgesia, might be of signi®cance in cardiac morbidity and
mortality, but this is outside the scope of this review.6 9
Conclusions
Several studies have addressed the problem of preoperative
evaluation of patients known to have, or at risk of, coronary
artery disease. Nevertheless, in the absence of large,
randomized, multicentre studies with clear-cut results, we
have to rely on evidence-based medicine and Bayesian
analysis for choosing preoperative strategies. The proposed
framework suggests a rather conservative approach, limit-
ing stress testing to intermediate-risk patients with suspicion
of a myocardium at risk of ischaemia, and coronary
angiography to situations where revascularization can
improve long-term survival. A specialized and costly test
is indicated only when the additional information provided
has a positive impact on patient outcome.
Fig 1 Algorithm for evaluating patients suffering from, or at risk of, myocardial ischaemia.
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Recent publications tend to show an increased risk of
proceeding with non-cardiac surgery less than 3 months
after coronary revascularization, which has been demon-
strated to have no place in preventing the ischaemic
complications of non-cardiac operations. Moreover, it is
frequently impossible to wait to treat myocardial ischaemia
when the patient requires a life-saving operation. In these
situations, recent studies, although scarce, have demon-
strated a marked bene®t of operating under the protection of
beta1-adrenergic antagonism. As postoperative infarction
has a better correlation with peri- and postoperative
ischaemic events than with preoperative ischaemia, it
seems logical to be aggressive in the prevention and
treatment of perioperative events. Finally, it appears that
the best strategy is very institution-speci®c. Every institu-
tion should construct its own guidelines, based on local
performances and results.
To help clarifying the comparison between different
publications with dissimilar methodologies, the references
are annotated into levels of evidence according to the
guidelines of evidence-based medicine. Level I of evidence
contains large studies with prospective, randomized selec-
tion of patients, blinding, and clear-cut results. Level II
contains small, randomized trials with uncertain results.
Level III comprises non-randomized studies with contem-
poraneous controls. Level IV corresponds to non-random-
ized studies with historical controls. Level V includes
uncontrolled case series and expert opinions. Theoretical
models, meta-analyses, and guidelines are not coded.
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